Results of Cuba’s Jusvinza drug to fight Covid-19 highlighted

Havana, Sep 2 (Prensa Latina) Scientist Maria del Carmen Dominguez on Friday highlighted the results from Cuba's Jusvinza drug, which contributed, among other national medicines, to fight the SARS-CoV-2 coronavirus, which causes Covid-19.

September 2, 2022
13:19

“The conference: ‘Jusvinza, an Immunomodulatory Peptide Derived from Human Heat-Shock Protein 60, for Treatment of Hyperinflammation in COVID-19 Patients,” by Dr. Maria del Carmen Dominguez, was of special interest to the Havana-based Genetic Engineering and Biotechnology Center (CIGB) reported on its Twitter account.

Dominguez is participating in the 6th International Congress “Controlling Diabetes and Its Most Severe Complications,” which opened in Cuba on Thursday.

Jusvinza, which received the award for technological innovation, is used in Cuba to treat severe and critical Covid-19 patients.

Designed by the CIGB, this peptide improves respiration parameters and inflammation markers, which leads to the recovery of people complicated by the pandemic, caused by the SARS-CoV-2 coronavirus.

Initially, this molecule was designed to treat diseases such as rheumatoid arthritis, but due to its capacity to reduce hyperinflammation caused by the coronavirus in severe, critical patients and prevent complications in high-risk patients, its use was authorized to fight the new coronavirus.

jg/iff/mgt/joe